Catheter Precision (NYSEAMERICAN:VTAK) Issues Earnings Results, Beats Expectations By $5.14 EPS

Catheter Precision (NYSEAMERICAN:VTAK – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($8.16) EPS for the quarter, topping analysts’ consensus estimates of ($13.30) by $5.14, FiscalAI reports. The company had revenue of $1.84 million during the quarter, compared to analyst estimates of $2.80 million. Catheter Precision had a negative return on equity of 37.53% and a negative net margin of 656.03%.

Catheter Precision Stock Performance

NYSEAMERICAN VTAK remained flat at $0.15 during trading on Monday. The company has a quick ratio of 0.18, a current ratio of 0.19 and a debt-to-equity ratio of 0.19. Catheter Precision has a fifty-two week low of $0.13 and a fifty-two week high of $3.20. The stock has a market cap of $2.17 million, a price-to-earnings ratio of -0.02 and a beta of -0.99. The business’s fifty day moving average is $0.73 and its 200 day moving average is $7.35.

Catheter Precision Company Profile

(Get Free Report)

Catheter Precision, Inc. is a medical device company focused on developing technologies for cardiac electrophysiology, a field involving the diagnosis and treatment of heart-rhythm disorders. Its products are designed to support physicians during procedures used to evaluate and treat cardiac arrhythmias, including ventricular tachycardia and other irregular heart rhythms. The company’s product portfolio includes the VIVO system, a noninvasive 3D cardiac mapping and navigation platform intended to help clinicians identify the origin of ventricular arrhythmias and plan catheter-ablation procedures.

Read More

Earnings History for Catheter Precision (NYSEAMERICAN:VTAK)

Receive News & Ratings for Catheter Precision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catheter Precision and related companies with MarketBeat.com's FREE daily email newsletter.